Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

• click to rate

  Posted by Two Blokes May 27 - Filed in Stock - 2 views
  
  PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.